Asuragen to Become First Shop to Sell miRNA Dx as Pancreatic Cancer Test to Debut in May

Whatever edge the product launch may give Asuragen in the miRNA diagnostic market is likely to be short-lived since its two chief rivals, Rosetta Genomics and Exiqon, are poised to introduce later this year their own miRNA tests, for different indications.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.